Search results

In case it's helpful, a recent review talking about immunoadsorption studies: Autoantibody targeting therapies in post COVID syndrome and myalgic encephalomyelitis/chronic fatigue syndrome, 2025, Wohlrab et al Refs:

Could you elaborate? If they can convincingly show that it is specifically the IgG that causes a change (with IgG depleted control solutions and whatnot), then I would think there is something in the IgG having a toxic effect. Is it that part about isolating IgG, or is it that differences in...

From the above thread: Here's the justification for this trial, from that website, auto-translated, with line breaks added:

Thread for this drug in a different condition: Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation, 2025, Smeitink et al.

SON4PEM Study: Sonlicromanol in Post-COVID: A Randomized, Double-blind, Placebo-controlled, Phase II Trial Brief Summary The aim of this randomized, doube-blind, placebo-controlled, phase II trial, is to study the effect of sonlicromanol on fatigue in patiënt with post-COVID who experience...

Severe Neurocognitive Manifestations in Healthy Young Individuals With COVID-19: A Case Series Background A growing number of patients suffering from neurocognitive symptoms related to COVID-19 were observed as the pandemic progressed. This article addresses severe neurological manifestations...

Evidence of Impaired Neuroimmune System in Post‐COVID Syndrome—A Whole Brain Magnetic Resonance Spectroscopy Study [Line breaks added] Abstract Chronic fatigue, mood disturbances, and cognitive deficits characterize the neurological post‐COVID syndrome (PCS). This study aimed to find out if...

One other option that might be worth considering is Karl Morten's lab at Oxford. Oxford allows for tax deductible donations from the US and other countries: There's a button for Americans to donate directly to his lab on the bottom of the page I linked above (it says "Donate via AFO"). I...

Sarah West is the supervisor. Here are her research papers: https://www.researchgate.net/scientific-contributions/Sarah-L-West-39109416 Most recent: Impacts of the Mindfulness Meditation Mobile App Calm on Undergraduate Students’ Sleep and Emotional State: Pilot Randomized Controlled Trial...

Interesting. I got the same result multiple times with Gemini. But when replacing "the lightning process" with other terms like "graded exercise therapy", "brain retraining", "EMDR", and "hydrocortisone", it works just fine. "Primal Trust" also causes the same refusal to answer. Also, asking...

Citation 17 of the following paper is Sato et al: B-cell repertoire sequencing reveals frequent rearrangements of IGHD5-5 in patients with systemic sclerosis, Fujii et al, Preprint, 2025 [Line breaks added]

It seems to me that the important parts are laid out in their papers, just that it's somewhat of a complicated process. I don't have the energy to try to go through it and parse it, but maybe this summary of their method I had claude.ai write will be helpful. This is from giving the AI the...

Also, the same gene/locus was already found in chronic pain, so it makes sense for pain researchers to look at. The replication in a past study of a somewhat similar condition also makes it less likely that this is a false positive finding.

Glancing at it right now. Yes this is why I am confused by the 'enduring symptoms' or 'symptom-based disorders' terms: The definition in Katharine's paper seems like it would include basically any chronic symptoms that aren't yet understood (i.e. would have included MS and Parkinson's in 1830...

Didn't he just get funding for dextro a few weeks ago? Would have been really fast to have a protocol registered already, right? I assume that'll start after some time. Seems like a good thing to have a dose-response study on LDN finally, even if unblinded. (Edit: doses are blinded)

I added this edit to a post above just now: Maybe someone can come up with one good reference that could be used for one good sentence. Trying to write an example - the first sentence is from the conclusion, and I added the second.

Isn't the latter a much bigger task that requires evidence that would be hard to fit inside an article of this length? The former is recounting symptoms from patients. The latter requires evidence of causality. What specific kinds of things would you have preferred to be included? Quotes from...

I don't think I was clear. My point was the term, as defined, should technically include basically any disease mechanism that science is still not able to describe. But the term still 'feels' like it's describing some specific group with a hypothesized mechanism that is basically FND, and so...

But before that. People still had the symptoms, but no one knew to look at a specific thing in the brain. It'd just be 'enduring symptoms', and then one day, they see the neuron damage, and it becomes a disease with a specific mechanism. My point is that all the uncharacterized 'enduring...

Thank you so much @kacheston for engaging. On the 'enduring symptoms' terminology - it feels odd to me since it's a new term I haven't seen, but if you were required to use it, I guess you had to. I can see how maybe it could be interpreted by people who want to interpret it this way as "those...